The Food and Drug Administration (FDA) plays a critical role in our fight against brain tumors. No new therapy is going to reach patients without the FDA’s approval. This year, there are several important pieces of legislation aimed at providing the FDA with the financial resources and policy tools it needs to accelerate approval of potential brain tumor therapies and evaluate them for safety and efficacy.
Congress is considering major legislation called the Prescription Drug User Fee Act (PDUFA) that must be re-authorized (enacted again) this year. We have an opportunity to be a strong voice for advancing brain tumor therapies today and to significantly improve opportunities for future therapies that seek the FDA’s approval.
First, find out more about the legislation. Then, send a note to your Members of Congress urging them to support legislation to empower the FDA to understand the latest brain tumor clinical trials and expedite approval of new therapies.
Thanks for making your voice heard.
David F. Arons, J.D.
Director of Public Policy